SCHEMBL11907307

SCHEMBL11907307

CC(=O)c1cccc(-c2ccc(N)c(C(=O)O)n2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K3 P46734 2/20 0.45
ECE1 P42892 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
PADI1 Q9ULC6 1/20 0.42
PADI3 Q9ULW8 1/20 0.42
PADI4 Q9UM07 1/20 0.42
PADI2 Q9Y2J8 1/20 0.42
KDM4E B2RXH2 2/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.36
IRAK4 Q9NWZ3 6/20 0.36
ALDH1A1 P00352 2/20 0.35
GRM5 P41594 1/20 0.35
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907722 0.82 MAP2K3 (0.51) MAP2K3ECE1PDE4APDE4BPDE4C
SCHEMBL11908134 0.81 CCR1 (0.52) MAP2K3ECE1IRAK4GRM5
SCHEMBL10556900 0.80 ALDH1A1 (0.50) ECE1KDM4EALOX15TSHRACMSD
SCHEMBL11906891 0.78 MAP2K3 (0.47) MAP2K3ECE1PDE4APDE4BPDE4C
SCHEMBL11907148 0.78 MAP2K3 (0.47) MAP2K3PDE4APDE4BPDE4CPDE4D
SCHEMBL11907840 0.78 BTK (0.44) MAP2K3TDP1
SCHEMBL11906960 0.76 MAP2K3 (0.49) MAP2K3KDM4EIRAK4ALDH1A1GRM5
SCHEMBL11907066 0.75 MAP2K3 (0.51) MAP2K3PADI1PADI3PADI4PADI2
SCHEMBL11909681 0.75 MAP2K3 (0.44) MAP2K3IRAK4
SCHEMBL11907402 0.74 BTK (0.48) MAP2K3PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MAP2K3 197/4885ECE1 1602/4885PDE4A 2601/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MAP2K3 197/4885ECE1 1602/4885PDE4A 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.